News >

IMiD-Free Triplet Leads to Prolonged PFS in Relapsed/Refractory Myeloma

Caroline Seymour
Published: Friday, Jan 17, 2020

Saad Z. Usmani, MD, FACP, chief of Plasma Cell Disorders and director of Clinical Research in Hematologic Malignancies at Levine Cancer Institute, Atrium Health

Saad Z. Usmani, MD, FACP

Findings from the phase III CANDOR trial have defined a new triplet option for patients with relapsed/refractory multiple myeloma, especially for those with lenalidomide (Revlimid)-exposed or -refractory disease, explained lead study author Saad Z. Usmani, MD, FACP.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication